GLP1R and type 2 diabetes mellitus: In the only other available randomized controlled study of a GLP-1 RA added to basal insulin, Seino et al. reported on the efficacy and safety of 20 mcg lixisenatide QD versus placebo in 311 Asian patients with type 2 diabetes inadequately controlled with basal insulin (±sulphonylurea) over a treatment period of 24 weeks 53.